港股异动 | 锦欣生殖大幅拉升逾8%创新高 纳入港股通标的即将生效
格隆汇9月6日丨辅助生殖第一股锦欣生殖(1951.HK)今日股价高开高走,大幅拉升超8%创新高。现报10.7港元,涨7.21%,暂成交1.45亿港元,最新总市值260亿港元。锦欣生殖是中美领先的辅助生殖提供商,今年6月25日上市之后,先后纳入恒生医疗保健、恒生港股通。8月25日锦欣生殖公布中期股东应占溢利同比增长1.52倍至1.7亿元。收益增加主要是由于集团成都及深圳业务的IVF患者数目及IVF取卵周期数增加。将美国业务自 2019年1月1日起的经营业绩纳入集团;及深圳中山医院于2018年上半年完成装修。值得注意的是,锦欣生殖被纳入恒生综指与港股通名单,这一变更将于9月9日(星期一)起生效,能够为锦欣生殖在资本市场提供更好的流动性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.